Better Health for All

Whitehawk Therapeutics, Inc. is an oncology therapeutics company developing next-generation antibody drug conjugate (ADC) cancer treatments, with its entire business devoted to improving health outcomes for patients with difficult-to-treat cancers.

The company estimates that nearly 750,000 patients in the US have PTK7-expressing cancers, which one of their ADCs targets. Whitehawk received IND clearance for HWK-007 and submitted an IND for HWK-016 in January 2026, with plans to bring all three assets to IND by mid-2026. The company demonstrates a strong commitment to health innovation, with research and development expenses of $71.942 million for the nine months ended September 30, 2025, and $8.8 million for the three months ended March 31, 2025. This represents a significant portion of their total expenses, indicating substantial investment in R&D. Whitehawk collaborates with Tempus AI to leverage real-world data for biomarker-driven research and clinical trial design, focusing on patient populations with unmet needs, and to establish concordance between RNA and IHC expression of targets. This collaboration involves using Tempus’ de-identified multimodal database, indicating excellent data practices with strong ethics framework. Regarding risk transparency, the company's quarterly report and press releases contain forward-looking statements made pursuant to safe harbor provisions and refer to risk factors described in SEC filings. This indicates a basic level of regulatory disclosure but lacks specific details on comprehensive health risk disclosures for their products. Whitehawk Therapeutics appointed David Dornan, PhD, as Chief Scientific Officer in February 2025, and had 18 full-time or part-time employees following the FYARRO Divestiture, which is a small workforce for a biopharmaceutical company. There is no specific information regarding ethical conduct of clinical trials, such as diversity in trial populations or transparency of results, beyond the general mention of collaboration for real-world analysis.

Fair Pay & Worker Respect

Whitehawk Therapeutics, Inc. (WHWK.US) has an overall employee rating of 3.6 out of 5 stars based on 21-22 reviews on Indeed.com, with review dates up to February 20, 2025.

This translates to an engagement score of approximately 72%. Glassdoor reviews indicate an employee rating of 2.7 out of 5 stars and a 38% recommendation rate. Some employee reviews mention potential wage violations, such as being cheated out of wages or delays when filing with the Department of Labor, but these are qualitative mentions without specific details or substantiation of formal violations. No specific, quantitative data was found for living wage coverage, CEO-to-median-employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, insecure contract share, or health insurance coverage.

No War, No Weapons

Whitehawk Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for cancer treatment, specifically antibody-drug conjugates (ADCs).

The provided articles describe its core business as pharmaceutical research and development, including a recent subsidiary sale and financing to support clinical data readouts for ADC assets. There is no evidence in any of the articles to suggest that Whitehawk Therapeutics, Inc. is involved in arms manufacturing, military contracts, dual-use technology with military applications, sales to sanctioned regimes, or any other activities related to war or weapons. Therefore, all KPIs related to the 'No War, No Weapons' value are not applicable to its core business operations.

Planet-Friendly Business

The provided articles offer general ESG risk scores for Whitehawk Therapeutics, Inc. (WHWK.US), such as a Sustainalytics ESG risk rating of 26.4 or 26, and a controversy level of 0.5.

However, they do not contain any specific, quantitative data points or detailed information regarding the company's performance on planet-friendly business practices. There is no evidence related to carbon emissions, renewable energy use, water management, waste diversion, green building certifications, climate-related policies, or any other specific environmental metrics. The articles explicitly state that no specific sustainability metrics, regulatory actions, violations, fines, or compliance issues are provided.

Respect for Cultures & Communities

The provided articles do not contain any specific, concrete data points or information relevant to Whitehawk Therapeutics, Inc. (WHWK.US) regarding its respect for cultures and communities. , while mentioning WHWK.US in its summary, primarily discusses 'White River Health' and explicitly states that no data pertinent to the requested metrics is present.

is from an unrelated educational institution and also contains no relevant information.

Safe & Smart Tech

No specific evidence was found in the provided articles regarding Whitehawk Therapeutics, Inc.'s performance or practices related to data protection, cybersecurity, or responsible AI. is a general overview of cybersecurity in healthcare and explicitly states it does not contain specific data related to WHWK.US.

is unavailable due to a 404 error.

Zero Waste & Sustainable Products

No specific, quantifiable information regarding Whitehawk Therapeutics, Inc.'s waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs was found in the provided articles.

General EPA guidance on hazardous waste pharmaceuticals and take-back programs was mentioned, but no specific actions or performance metrics for Whitehawk Therapeutics, Inc. were provided.